CYTOMEGALOVIRUS-INFECTION AS A COMPLICATION OF OKT3 THERAPY IN KIDNEY-TRANSPLANT RECIPIENTS

被引：4

作者：

CONLON, PJ ^{[1
]}

CARMODY, M ^{[1
]}

DONOHOE, J ^{[1
]}

SPENCER, S ^{[1
]}

SMYTH, E ^{[1
]}

WALSHE, JJ ^{[1
]}

机构：

[1] BEAUMONT HOSP,DEPT NEPHROL,POB 1297,BEAUMONT RD,DUBLIN 9,IRELAND

来源：

IRISH JOURNAL OF MEDICAL SCIENCE | 1992年 / 161卷 / 11期

关键词：

D O I：

10.1007/BF02983769

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We compared the incidence of clinical CMV illness in 25 renal transplant recipients treated with OKT3 for steroid resistant cellular rejection with 88 renal transplant patients treated only with conventional immunosuppression (cyclosporin A and steroids). Nine (36%) patients in the OKT3 group developed CMV illness compared to (2.3%) amongst those treated conventionally (p<0.0005). Patients who received OKT3 were divided into four groups according to the CMV antibody status of the donor and recipient. Six of the 9 episodes of CMV infection occurred in patients not previously exposed to CMV, who received a kidney from a CMV positive donor. Three (12%) of the patients treated with OKT3 died of CMV disease. A further 2 patients died of other causes giving an overall mortality in the OKT3 treated group of 20%. We concluded that when OKT3 therapy is used in association with donor/recipient CMV mismatch it is associated with a high CMV morbidity and mortality.

引用

页码：630 / 632

页数：3

共 15 条

[1] Van Son E.J., The Th. Cytomegalovirus infection after organ transplantation: an update with special emphasis on renal transplantation, Transplant Int., 2, pp. 147-164, (1989)
[2] Simmonds R., Lopez C., Balfour H., Kalis J., Rattazzi L., Majarian J., Cytomegalovirus: Clinical virological correlations in renal transplant recipients, Ann. Surg., 180, pp. 623-632, (1974)
[3] Kurtz J.B., Thompson J.F., Ting A., Pinto A., Morris P.J., The problem of cytomegalovirus infection in renal allograft recipients, Quarterly Journal of Medicine, 211, pp. 341-349, (1984)
[4] Fryd D., Peterson P., Ferguson R., Simmons R., Balfour H., Najarian J., Cytomegalovirus as a risk factor in renal transplantation, Transplantation, 30, pp. 436-439, (1980)
[5] Lewis R., Johnson P., Golden D., van Buren C., Kerman R., Kahan B., The adverse impact of Cytomegalovirus infection on clinical outcome in Cyclosporin-Prednisone treated renal allograft recipients, Transplantation, 45, pp. 353-359, (1988)
[6] Smiley M.L., Wlodavir C.G., Grosmann R.A., Barker C.F., Perloff L.J., Trustin N.B., Starr S.E., Et al., The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation, Transplantation, 40, pp. 157-161, (1985)
[7] Velasco N., Catto G.R.D., Edward N., Engest J., Et al., The effect of the dosage of steroids on the incidence of cytomegalovirus infections in renal transplant recipients, J. Infect. Dis., 2, pp. 69-78, (1982)
[8] Reynolds D.W., Stango S., Alford C.A., Laboratory diagnosis of cytomegalovirus infections, diagnostic procedures for viral, ricketsial and chlamydial infections, pp. 399-439, (1979)
[9] Norman D.J., Shield C.F., Bary J., Funnell M.B., Lemmon J., A US clinical study of orthoclone OKT3 in renal transplantation, Transplant-Proc., 19, pp. 21-27, (1987)
[10] Choohng-Sah, Stratta R.J., Fox B. C, Sollonger H.W., Beizer F.O., Maki D.G., Increased infections associated with the use of OKT3 for treatment of steroid resistant rejection in renal transplantation, Transplantation, 45, 1, pp. 68-73, (1988)

← 1 2 →